INTRODUCTION {#s1}
============

Chronic kidney disease (CKD) is considered to be a major public health problem \[[@GFV131C1]\]. CKD has an important impact both at the patient level, by decreasing the quality of life and life expectancy, and at the population level, by increasing health-care costs and the demand for health-care services.

Since CKD prevalence estimation is central to CKD management and prevention planning at the population level \[[@GFV131C2]\], it is not surprising that many publications report CKD prevalence in the general population. It is common research practice to put study results into context by comparing them with previous publications to identify the regional CKD burden, assessing the impact on regional health-care systems and for tailoring preventive strategies to communities. In the case of CKD prevalence, such comparisons are likely hampered as CKD prevalence estimations are influenced by study population characteristics and by the methods used to assess kidney function \[[@GFV131C3], [@GFV131C4]\]. To realistically compare CKD prevalence across different population-based studies, methodological factors should be taken into account.

The purpose of this systematic literature review was to (i) identify all studies reporting on CKD prevalence in the European adult general population and (ii) to describe the methodology used in these studies. The findings from this review are utilized to provide recommendations that may help investigators to optimize both the design and the reporting of future CKD prevalence studies, which will enhance comparability of results across studies.

METHODS {#s2}
=======

Search strategy {#s2a}
---------------

A systematic literature search was performed in PubMed, MEDLINE and EMBASE to identify all original research articles reporting the prevalence of CKD in the adult general population. As Kidney Disease Outcomes Quality Initiative (KDOQI) published a guideline on CKD definition \[[@GFV131C5]\] in 2002, we included articles published between 1 January 2003, which is one year after the publication of the KDOQI guideline, and 1 November 2014, when our search was last updated. The database-specific search queries are presented in the [Supplementary data, Appendix S1](http://ndt.oxfordjournals.org/lookup/suppl/doi:10.1093/ndt/gfv131/-/DC1). Additionally, the representatives of national kidney foundations, renal registries and expert nephrologists in 39 European countries were asked to provide information on any relevant studies.

Study selection {#s2b}
---------------

Publications that presented original research, were designed to select a representative sample of a European adult general population and reported a CKD prevalence estimate were included. We excluded studies that ended subject recruitment prior to 1996 and studies lacking glomerular filtration rate (GFR) estimation based on serum creatinine. Cystatin C-based estimated GFR (eGFR) will lead to higher CKD prevalence estimates than creatinine-based eGFR \[[@GFV131C6]\]. For the sake of comparability, we chose not to include publications that solely reported cystatin C-based prevalence estimates. No language restrictions were applied. The literature search was done by two investigators (KB, ED). Any study that was judged relevant on the basis of its title was retrieved in abstract form, and if relevant, in full-text form. Any doubt about eligibility was resolved by discussion with another investigator (VS).

Data extraction {#s2c}
---------------

All publications were initially seen by one investigator (KB) and then independently reassessed by two additional investigators (ED for the first half and AK for the second half). For studies with multiple eligible publications, we selected the publication with a primary objective of reporting CKD prevalence or the most recent publication. Publications were assessed on method of population selection, which included the sampling frame (i.e. source used to identify subjects) and the sample design (i.e. the method of sample selection). Additionally, we extracted information on the assessment of kidney function. The extracted data were categorized as follows: Creatinine assay was categorized as enzymatic, Jaffe, modified Jaffe, compensated Jaffe or unclear. The Jaffe method is known to suffer from interference by other substances \[[@GFV131C7]\], and multiple adaptations have been implemented to improve method specificity \[[@GFV131C7]\]. The compensated and modified Jaffe assays were developed to improve method specificity and minimize susceptibility of interfering substances \[[@GFV131C7]\]. The compensated Jaffe method is the use of a manufacturer-specific mathematical compensation \[[@GFV131C8]\]. The modified Jaffe assays are modifications of the method such as deproteinization of the sample prior to analysis or the addition of potassium ferricyanide \[[@GFV131C9]\].Calibration was categorized as calibrated to the standardized isotope dilution mass spectrometry (IDMS) or calibrated by another method or calibrator.Urinary albumin assay was categorized as dipstick, immunoassay (including both nephelometric and turbidometric immunoassays) or other.The CKD definition was categorized as use of the KDOQI 2002 definitions \[[@GFV131C5]\] or use of other definitions. Use of chronicity criterion, i.e. persistence of albuminuria or decreased eGFR for at least 3 months, was assessed.Ethnicity reporting was categorized as 'yes' if publication reported collection of ethnicity data and as 'no' if 'ethnicity' data were not collected or if those were not reported.

Finally, we extracted the following data on presentation of CKD prevalence results: the use of 95% confidence intervals (95%CI), the use of standardization of the prevalence estimate to a reference population and the presentation of results by age group and sex. If CKD prevalence was not the main focus of the publication, the use of 95%CI was rated as not applicable (n/a). The data extraction form is shown in the [Supplementary data, Appendix S2](http://ndt.oxfordjournals.org/lookup/suppl/doi:10.1093/ndt/gfv131/-/DC1).

RESULTS {#s3}
=======

Study selection {#s3a}
---------------

Figure [1](#GFV131F1){ref-type="fig"} shows the selection process of inclusion and exclusion of publications in a flow chart. We retrieved 2000 individual publications of which only one study was solely identified through contacting national representatives. A total of 1842 publications were excluded based on title or abstract. Twenty-five publications were excluded as the study was not designed to select a representative sample of the general population, 9 studies were excluded as they ended recruitment prior to 1996 and 42 publications were excluded for not presenting a CKD prevalence estimate. Eighty-two publications fulfilled the inclusion criteria. Eighteen studies had multiple publications, highlighting various aspects of CKD (overall 34 publications). Finally, we included 48 publications of individual studies for the data extraction. FIGURE 1:Flow chart of publication selection.

Data extraction {#s3b}
---------------

Table [1](#GFV131TB1){ref-type="table"} describes the method of general population sample selection including the response per study. Details on the laboratory assessment of kidney function, the CKD definition used and on the reporting of CKD prevalence are presented in Table [2](#GFV131TB2){ref-type="table"}. Table 1.Description of the method of general population sample selection per studyAuthor (Ref.)Study nameCountryTime periodNumber of subjects, *N*Age rangeSampling frameSample designResponse, %Aumann *et al.* \[[@GFV131C10]\]SHIPGermany2001--6283025--88Not specified^a^Multistage sampling69Bongard *et al.* \[[@GFV131C11]\]MONA LISAFrance2006--7472735--75Electoral rollsAge and sex stratifiedNot givenBrowne *et al.* \[[@GFV131C12]\]SLANIreland2007109845+Other (Geo directory)Multistage random sampling: by area and region66Capuano *et al.* \[[@GFV131C13]\]VIPItaly1998--99 and 2008--9240025--74Electoral rollsAge and sex stratifiedNot givenChristensson *et al.* \[[@GFV131C14]\]GASSweden2001--4281560--93CensusStratified, age, sex and urban/rural location60Chudek *et al.* \[[@GFV131C15]\]PolSeniorPoland2007--11379365+Not specified^a^Not specified^a^32Cirillo *et al.* \[[@GFV131C16]\]Gubbio Population StudyItalyNot specified457418--95Not specified^a^Not specified^a^Not given^a^Codreanu *et al.* \[[@GFV131C17]\]Early Detection and Intervention Program for Chronic Renal and Cardiovascular Disease in the Rep MoldovaMoldova2006--797318--77Not specifiedNot specifiedNot givenDe Nicola *et al.* \[[@GFV131C18]\]CARHESItaly2008407735--79Electoral rollsAge and sex stratified45Delanaye *et al.* \[[@GFV131C19]\]Belgium2008--9199245--75Not specifiedVoluntary natureNot givenDonfrancesco *et al.* \[[@GFV131C20]\]MATISSItaly1993--96292420--79Electoral rollsAge- and sex-stratified random sample60Formiga *et al.* \[[@GFV131C21]\]OctabaixSpain200932885Not specified^a^Not specified^a^Not givenFraser *et al.* \[[@GFV131C22]\]HSEEngland2009--10579916+Other (address list)Random two-stage sampleNot given^a^Gambaro *et al.* \[[@GFV131C23]\]INCIPEItaly2006362940+General practitioner listRandom sample62Gianelli *et al.* \[[@GFV131C24]\]InChiantiItaly1998--200067665+Not specifiedMultistage stratified random sampleNot givenGoek *et al.* \[[@GFV131C25]\]KORAGermany1999--1110454--75Not specifiedNot specifiedNot givenGu *et al.* \[[@GFV131C26]\]FLEMENGHOBelgium2005--1079718--89Not specifiedNot specified78Guessous *et al.* \[[@GFV131C27]\]Swiss Study on Salt intakeSwitzerland2010--11114515+Other (phone directory)Age- and sex-stratified random sample10Hallan *et al.* \[[@GFV131C28]\]HUNT 2Norway1995--9765 18120+Not specifiedAll inhabitants70Hernandez *et al.* \[[@GFV131C29]\]IMAPSpain2007227018--80Not specified^a^Random sampleNot givenJuutilainen *et al.* \[[@GFV131C30]\]FINRISKFinland2002 and 200711 27725--74CensusAge- and sex-stratified random sample71 in men\
74 in womenLieb *et al.* \[[@GFV131C31]\]MONICA/KORAGermanyNot specified118725--74Not specifiedAge- and sex-stratified random sample71Meuwese *et al.* \[[@GFV131C32]\]Leiden 85 + studyNetherlands1997--9955885Not specifiedAll in birth cohort87Nitsch *et al.* \[[@GFV131C33]\]BWHHSUK1999--2001385160--79Not specified^a^Random sample60Nitsch *et al.* \[[@GFV131C34]\]SAPALDIA 2Switzerland1991 and 2002631718+Not specified^a^Random sample73Otero *et al.* \[[@GFV131C35]\]EPIRCESpain2004--8274620+CensusAge-, sex- and region-stratified random sample43Pani *et al.* \[[@GFV131C36]\]SardiNIA studyItaly2001--447114--102Not specified^a^Not specified^a^56Pattaro *et al.* \[[@GFV131C37]\]MICROSItaly2002--3119918+Not specified^a^Not specified^a^Not givenPonte *et al.* \[[@GFV131C38]\]CoLausSwitzerland2003--6592135--75Population registryRandom sample41Redon *et al.* \[[@GFV131C39]\]PREV-ICTUSSpain2005641960+General practitioner listsRandom sample72Robles *et al.* \[[@GFV131C40]\]HERMEXSpainNot specified281325--79Other (health-care system database)Age- and sex-stratified random sample83Roderick *et al.* \[[@GFV131C41]\]MRC Older Age StudyUK1994--9913 17975+General practitioner listPractices stratified by mortality score and deprivation score73Rothenbacher *et al.* \[[@GFV131C42]\]ActiFE UlmGermany2009--10147165+CensusRandom sample20Rutkowski *et al.* \[[@GFV131C43]\]PolNefPoland2004--52476n/aOther (address list)Random sample26Sahin *et al.* \[[@GFV131C44]\]Turkey2005107918--95Not specifiedAge, sex and region stratifiedNot givenSchaeffner *et al.* \[[@GFV131C45]\]BISGermany201157070+Not specified^a^Not specified^a^Not givenScheven *et al.* \[[@GFV131C46]\]PREVENDThe Netherlands1997--98812128--75Not specifiedAll inhabitants48Stasevic *et al.* \[[@GFV131C47]\]Kosovo + Metohia200642318+Not specifiedAll inhabitants43Stengel *et al.* \[[@GFV131C48]\]3CFrance1991--2001870565+Electoral rollsRandom sample37Suleymanlar *et al.* \[[@GFV131C49]\]CREDITTurkeyNot specified10 05618+Not specifiedAge, sex and region stratifiedNot givenTavira *et al.* \[[@GFV131C50]\]RENASTURSpain2010--1259255--85Not specifiedRandom sampleNot givenVan Pottelbergh *et al.* \[[@GFV131C51]\]CrystalRussia200961165--91General practitioner listAll registered on list66Viktorsdottir *et al.* \[[@GFV131C52]\]RHSIceland1967--9619 25633--85Not specifiedAll in birth cohortNot givenVinhas *et al.* \[[@GFV131C53]\]PREVADIABPortugal2008--9516720--79Other (universal health card)Age, sex and region stratified84Wasen *et al.* \[[@GFV131C54]\]Finland1998--99124664--100Not specifiedAll residents born ≤193383Wetmore *et al.* \[[@GFV131C55]\]Iceland2001--3163018+Not specifiedRandom sample71Zambon *et al.* \[[@GFV131C56]\]ProV.A.Italy1995--97306365+Other (health district registries)Age- and sex-stratified random sample77 in men\
64 in womenZhang *et al.* \[[@GFV131C57]\]ESTHERGermany2000--2980650--74General practitionersAll participants who underwent a general health check-upNot given[^1][^2] Table 2.Laboratory assessment of kidney function, CKD definition used and details on the reporting of CKD prevalence per studyAuthor (Ref.)Creatinine assayIDMSAlbuminuriaCKD definitioneGFR equationEthnicityCIAge and sex standardizedStratified prevalenceAumann *et al.* \[[@GFV131C10]\]JaffeOthern/a2CKD-EPI + otherYesn/aNoYes: otherBongard *et al.* \[[@GFV131C11]\]JaffeNon/a2MDRD (old)NoYesYes to national pop.NoBrowne *et al.* \[[@GFV131C12]\]Modified JaffeYesOther1 + 2CKD-EPI + new MDRDNoYesYes to national pop.Yes: age, sex and otherCapuano *et al.* \[[@GFV131C13]\]Modified JaffeNon/a2CGNoNoYes to national pop.Yes: age, sex and otherChristensson *et al.* \[[@GFV131C14]\]UnclearOthern/aOtherCKD-EPI, MDRD (old) + CGYesNoNoYes: age and sexChudek *et al.* \[[@GFV131C15]\]JaffeUnclearIf dipstick − → immunoassay1 + 2 + 3CKD-EPINoNoNoYes: age, sex and otherCirillo *et al.* \[[@GFV131C16]\]Modified JaffeNoImmunoassay2MDRD (old)YesYes for *N*\
Not for %Yes to national pop.Yes: age and sexCodreanu *et al.* \[[@GFV131C17]\]UnclearNoOther2 + 3MDRD (old)NoNoNoYes: age, sex and otherDe Nicola *et al.* \[[@GFV131C18]\]EnzymaticYesImmunoassay1 + 2 + 3CKD-EPINoYesNoNoDelanaye *et al.* \[[@GFV131C19]\]Compensated JaffeYesn/a2CKD-EPI + new MDRDNoNoNoYes: sexDonfrancesco *et al.* \[[@GFV131C20]\]EnzymaticYesn/a2CKD-EPINoNoNoYes: sexFormiga *et al.* \[[@GFV131C21]\]Compensated JaffeNon/a2MDRD (old)NoNoNoNoFraser *et al.* \[[@GFV131C22]\]EnzymaticYesNot specified1 + 2 + 3 + otherCKD-EPI + new MDRDYesNoUnclearYes: otherGambaro *et al.* \[[@GFV131C23]\]Modified JaffeOtherIf dipstick + → immunoassay1 + 2 + 3CKD-EPIYesYesYes to US pop.Yes: age, sex and otherGianelli *et al.* \[[@GFV131C24]\]Modified JaffeNon/a2MDRD (old) and CGNoNoNoNoGoek *et al.* \[[@GFV131C25]\]Compensated JaffeUnclearn/a2CKD-EPINon/aNoNoGu *et al.* \[[@GFV131C26]\]Modified JaffeUnclearNot specified2CKD-EPI + MDRD (old)NoNoNoNoGuessous *et al.* \[[@GFV131C27]\]Compensated JaffeUnclearUnclear1CKD-EPIYesn/aNoNoHallan *et al.* \[[@GFV131C28]\]JaffeOtherImmunoassay1 + 2 + 3New MDRDYesYesYes to national + US pop.Yes: age, sex and otherHernandez *et al.* \[[@GFV131C29]\]Not specifiedUnclearNot specified1 + otherCKD-EPIYesn/aNoYes: otherJuutilainen *et al.* \[[@GFV131C30]\]EnzymaticYesn/a2 + otherCKD-EPI + new MDRDNonoNoYes: age and sexLieb *et al.* \[[@GFV131C31]\]EnzymaticNoImmunoassay3 + otherMDRD (old)Non/aNoNoMeuwese *et al.* \[[@GFV131C32]\]JaffeNon/a2CKD-EPI + MDRD (old)Non/aNoNoNitsch *et al.* \[[@GFV131C33]\]Modified JaffeOthern/a2MDRD (old)Yesn/aNoYes: otherNitsch *et al.* \[[@GFV131C34]\]JaffeOthern/a2MDRD (old) and CGYesYesNoYes: age and sexOtero *et al.* \[[@GFV131C35]\]UnclearUnclearUnclear1 + 2MDRD (old)YesYesYes to national pop.Yes: age, sex and otherPani *et al.* \[[@GFV131C36]\]Not specifiedOtherNot specified1 + 2 + 3CKD-EPI + new MDRDNoYesNoYes: age and sexPattaro *et al.* \[[@GFV131C37]\]EnzymaticYesn/a2CKD-EPI, new MDRD + otherNoYesNoYes: agePonte *et al.* \[[@GFV131C38]\]Compensated JaffeYesImmunoassay1 + 2 + 3CKD-EPI + new MDRDYesYesNoYes: age and sexRedon *et al.* \[[@GFV131C39]\]JaffeYesImmunoassay2CGNon/aNoNoRobles *et al.* \[[@GFV131C40]\]Modified Jaffe + enzymaticNoDipstick2 + otherCKD-EPI + new MDRDYesYesYes to EU pop.Yes: age and sexRoderick *et al.* \[[@GFV131C41]\]Modified JaffeYesImmunoassay2 + otherMDRD (old)NoYesNoYes: age and sexRothenbacher *et al.* \[[@GFV131C42]\]Modified JaffeNoIf dipstick + → immunoassay1 + 2 + 3CKD-EPI + new MDRDNoNoNoYes: age and sexRutkowski *et al.* \[[@GFV131C43]\]Modified JaffeUnclearn/a1 + 2 + 3MDRD (old)NoNoNoNoSahin *et al.* \[[@GFV131C44]\]EnzymaticYesNot specified2New MDRDNoNoNoYes: age, sex and otherSchaeffner *et al.* \[[@GFV131C45]\]UnclearUnclearImmunoassay2CKD-EPI + otherYesn/aNoNoScheven *et al.* \[[@GFV131C46]\]Modified JaffeUnclearIf dipstick + → immunoassay1 + 2 + 3CKD-EPINon/aNo\*NoStasevic *et al.* \[[@GFV131C47]\]JaffeYesUnclear2 + 3 + otherMDRD (old)NoNoNoNoStengel *et al.* \[[@GFV131C48]\]JaffeYes^a^Immunoassay1 + 2CKD-EPI + new MDRDNoNoNoYes: age and sexSuleymanlar *et al.* \[[@GFV131C49]\]Not specifiedNoNot specified1 + 2 + 3MDRD (old)YesNoYes to national pop.Yes: age and sexTavira *et al.* \[[@GFV131C50]\]Modified JaffeNon/a2MDRD (old)Yesn/aNoNoVan Pottelbergh *et al.* \[[@GFV131C51]\]Modified JaffeNoDipstick2MDRD (old) and CGNoNoNoYes: age and sexViktorsdottir *et al.* \[[@GFV131C52]\]Modified JaffeNon/a1 + 2 + 3MDRD (old) and CGYesNoYes to global pop.Yes: age and sexVinhas *et al.* \[[@GFV131C53]\]JaffeUnclearImmunoassay2MDRD (old)NoYesYes to national pop.Yes: age, sex and otherWasen *et al.* \[[@GFV131C54]\]UnclearYesn/a2 + otherNew MDRD and CGNoNoNoYes per sexWetmore *et al.* \[[@GFV131C55]\]JaffeOtherDipstick2New MDRD and CGYesNoNoNoZambon *et al.* \[[@GFV131C56]\]Modified JaffeNoImmunoassay2 + otherCKD-EPI and MDRD (old)Yesn/aYes to national pop.NoZhang *et al.* \[[@GFV131C57]\]Modified JaffeOthern/a2 + otherMDRD (old)NoNoNoYes: age, sex and other[^3][^4]

### Population selection {#s3b1}

All studies combined described a total of 247 342 subjects. The size of the study population ranged from 328 to 65 181 subjects. Twenty-three studies (48%) included virtually the entire age range of the adult population. The remaining (*n* = 25; 52%) studies restricted the recruitment of subjects to a higher age range.

Four studies (8%) used census data as the sampling frame to identify eligible study subjects. More than half of the studies (*n* = 26; 54%) did not report the sampling frame used. Fourteen studies (29%) were designed to select their population by age and sex stratification, and 12 studies (25%) selected a random sample. Ten studies (21%) did not provide details on the sample design, six of which referred to previous publications for more details.

The response was given in 31 studies (65%) and ranged from 10 to 87%. Of the 17 studies that did not report a response, 2 studies referred to a previous publication for details regarding responders and non-responders.

### Assessment of kidney function {#s3b2}

Serum creatinine was determined by Jaffe assay in the majority of studies (*n* = 32; 67%) and by enzymatic assay in six (13%) studies. Only few creatinine assays were calibrated to IDMS (*n* = 14; 29%). Urinary markers for kidney disease were assessed in 29 studies (60%), 15 of which (31%) used immunoassay to detect albuminuria. Seven studies (15%) used dipsticks to identify proteinuria, with confirmation of albuminuria by immunoassay in four studies (8%).

### CKD definition {#s3b3}

Almost all studies (*n* = 44; 92%) defined CKD as eGFR below 60 mL/min/1.73 m^2^. Eighteen studies (38%) reported CKD prevalence defined as eGFR below 60 mL/min/1.73 m^2^ and/or the presence of albuminuria \>30 mg/g, and 15 studies (32%) reported CKD prevalence defined as albuminuria \>30 mg/g. Although 10 studies (21%) additionally reported CKD according to another definition, only one study exclusively reported a CKD prevalence not defined by KDOQI.

The Modification of Diet in Renal Disease (MDRD) equation for unstandardized creatinine was used to estimate GFR in 22 studies (46%), and the MDRD equation for standardized creatinine was used in 14 studies (29%). Twenty-five studies (52%) used the CKD Epidemiology Collaboration (CKD-EPI) equation, and nine studies (19%) used the Cockcroft and Gault equation. Even though both the CKD-EPI and MDRD equations include an ethnicity variable, only 18 studies (38%) reported collecting ethnicity data. Eleven studies (23%) did not indicate whether ethnicity data were collected.

### Reporting results {#s3b4}

CKD prevalence reporting was the main objective in 36 publications, of which 39% reported a 95%CI. An age- and sex-standardized prevalence was reported in 12 studies (25%), of which 9 standardized to their national population. Although two studies standardized their population to the US population, only one study standardized to the European population. The presentation of CKD prevalence by strata was done by 31 studies, and these studies presented the CKD prevalence stratified per risk factor, mostly by age (*n* = 24; 50%) and by sex (*n* = 26; 54%).

DISCUSSION {#s4}
==========

We assessed 48 publications, published between 1 January 2003 and 1 November 2014, reporting CKD prevalence for the adult general population in 20 European countries. The results of this systematic literature review revealed considerable variation in general population sample selection methods and assessment of kidney function across studies. Moreover, often a clear description of the methods used was lacking, and the reporting of CKD prevalence was heterogeneous. These factors may have considerable influence on the prevalence estimates of CKD and need to be taken into account to allow comparison of CKD prevalence across studies.

Population sample selection {#s4a}
---------------------------

Although we restricted our search to studies that were designed to be representative of the general population, we observed great heterogeneity in population sample selection methods. Part of this variation was found in the sampling frame used to identify contact details of eligible subjects. The sampling frame should ideally include the entire target population \[[@GFV131C58]\], which in this case is the entire general population. National census or population registry data are ideal for sampling the general population; in principle, these should include all inhabitants of a country or region. However, general population surveys are typically limited to community-dwelling subjects who are physically and mentally capable to participate in such studies. At old age, a substantial proportion of those with age-related chronic diseases such as CKD may no longer fulfill these inclusion criteria, which may lead to substantial underestimation of the true prevalence of such diseases. In such circumstances, depending on the health system or country, general practitioner list- or registry-based approaches might be required to provide more valid estimates of true prevalence.

Additionally, there existed great variation in sample design. For example, some studies first performed stratification of population by age and sex, whereas others invited all inhabitants in the selected region. Both the sampling frame and sample design influence the response and non-response bias \[[@GFV131C58]\], which in turn may influence the representativeness of the resulting sample for the general population and consequently of the CKD prevalence estimate. Collecting information on non-responders may help to assess the possibility and likely direction of non-response bias \[[@GFV131C58]\].

Assessment of kidney function {#s4b}
-----------------------------

### Serum creatinine and albuminuria measurements {#s4b1}

There was great variation in the laboratory methods used in studies that reported details of those methods, especially in the calibration of serum creatinine. Differences in creatinine assays are important to take into account in CKD prevalence comparisons, as Jaffe methods overestimate serum creatinine and therefore overestimate CKD prevalence \[[@GFV131C59]\]. In 2006, IDMS standardization has been implemented to reduce the systematic bias in creatinine determination and to increase inter laboratory comparability \[[@GFV131C7]\]. The publications that clearly reported the use of IDMS standardization were only published in 2010 or later.

### Ethnicity {#s4b2}

In equations used to estimate GFR, like MDRD and CKD-EPI, the variable 'ethnicity' is included to adjust for ethnicity-specific differences. Ethnicity may, therefore, influence CKD prevalence estimates; even so, less than half of the publications reported collection of ethnicity data. Since in most European countries the vast majority of the European population is Caucasian, the lack of ethnicity data is unlikely to influence the CKD prevalence of most countries. In the future, however, the proportion of Caucasian subjects in the European population may change, making the collection of ethnicity data more important.

### CKD definition {#s4b3}

Despite the KDOQI guideline on CKD that was published in 2002 \[[@GFV131C5]\] and updated by Kidney Disease Improving Global Outcomes (KDIGO) in 2012 \[[@GFV131C60]\], we observed great variation in the definition of CKD, both in eGFR equations used and in cut-off values for both eGFR and albuminuria. For future studies, it is advisable to report CKD as recommended in the updated KDIGO guideline, including six eGFR categories and three albuminuria categories, as this classification allows presentation by mortality and progression risk \[[@GFV131C61]\]. The chronicity criterion was never used, mainly because follow-up data on serum creatinine were not collected. In more recent studies, CKD was most commonly defined using the CKD-EPI equation, as recommended by KDOQI \[[@GFV131C5]\].

Reporting methods {#s4c}
-----------------

A clear description of the population sample selection methods and assessment of kidney function may facilitate a more fair comparison of CKD prevalence across studies. Studies should, therefore, preferably report this in detail in the method section of their publication. Unfortunately, many studies did not report the sampling frame used. In addition, information about biological sample collection (e.g. nature of collecting procedure, participants conditions, time between sampling and further processing) and sample storage conditions (duration of storage, thawing cycles, etc.) should also be reported \[[@GFV131C62]\].

Reporting results {#s4d}
-----------------

Another observed difference was the presentation of the results on CKD prevalence estimates. Part of this variation is likely explained by the fact that CKD prevalence was not the main focus of 12 publications. However, even in publications with the main focus on CKD prevalence, there was great variation in reporting. All studies did report unadjusted prevalence estimates, yet they were mostly reported without a 95%CI. The reporting of the 95%CI is necessary as it provides an indication of how much uncertainty there is in the prevalence estimate.

Future studies should preferably report CKD prevalence standardized to the European population to enable international comparison, at least across Europe. In the case of regional prevalence estimates, additional standardization to the national population is required for within-country comparison. This standardization is essential when comparing CKD prevalence estimates from different countries or regions to avoid the influence of differences in national or regional age and sex distributions.

European CKD Burden Consortium {#s4e}
------------------------------

In 2012, the European CKD Burden Consortium was established, including both nephrologists and epidemiologists, to enhance comparability of CKD prevalence across European regions and countries.

[Box 1](#GFV131BX1){ref-type="sec"} provides an overview of the methodology used by the European CKD Burden Consortium to compare CKD prevalence results across different general population-based studies in Europe. This methodology facilitates comparability by providing a detailed description of the population selection method and the response of each study to help assess representativeness of the study population sample. Additionally, the figures and tables clearly show the serum creatinine method used (i.e. Jaffe versus enzymatic) and whether IDMS calibration standardization was used.

###### Recommended methodology for comparison of CKD prevalence results across general population-based studies as used by European CKD Burden Consortium

Recommended toolsDetails1. General population sampling Sampling methodsDescribe: -- sampling frame, i.e. source used to identify subjects-- sample design, i.e. method of subject selection (e.g. age stratified, random) ResponseReport the response in percentages2. Assessment of kidney function Serum creatinine assayDescribe assay used, i.e. Jaffe or enzymatic Albuminuria assayDescribe assay used, e.g. immunoassay and dipstick IDMS calibration standardizationDescribe if IDMS calibration standardization was used (yes/no) CKD definitionUse of the same definition of CKD: [CKD Stages 1--5:]{.ul}eGFR \< 60mL/min/1.73 m² calculated by the CKD-EPI equation, and/or ACR \> 30 mg/g.[CKD Stages 3--5:]{.ul} eGFR \< 60mL/min/1.73 m² calculated by CKD-EPI equation.3. Presentation of results CKD prevalence estimateReport:-- unadjusted and adjusted CKD prevalence (e.g. standardized to the EU27 population)-- 95%CI CKD prevalence estimate by strataReport:-- stratified by age groups: 20--44, 45--64, 65--74 and 75--84 years-- stratified by diabetic, hypertension and obesity status Serum creatinine determinationIndicate in tables and figures which studies use:-- Jaffe or enzymatic assay-- IDMS calibration standardization

ACR, urinary albumin to urinary creatinine ratio; IDMS, isotope dilution mass spectrometry.

Furthermore, a uniform definition of CKD based on the KDIGO guideline was established \[[@GFV131C60]\]. CKD was defined as the presence of albuminuria \>30 mg/g and/or an eGFR of \<60 mL/min/1.73 m^2^ as calculated by the CKD-EPI equation. The chronicity criterion was not applied, for none of the assessed general population-based studies had this available.

The Consortium will additionally harmonize reporting of results in their publications. All CKD prevalence estimates will be presented as unadjusted rates and standardized to the EU27 population of 2005 \[[@GFV131C63]\] and include a 95%CI. As the occurrence of CKD is associated with age and not all study populations cover the entire range of the adult population, the CKD prevalence will also be presented for different age ranges, i.e. 20--44, 45--64, 65--74 and 75--84 years. Additionally, the prevalence estimates will be presented with stratification for the presence of the following risk factors: diabetes, hypertension and obesity. This stratification is useful to determine if differences in CKD prevalence are caused by differences in risk factor presence or differences in overall health status of the general population. Whether disparities in CKD prevalence are explained by important risk factors for CKD will guide policy makers to focus on secondary or primary prevention.

Implications {#s4f}
------------

This systematic literature review revealed considerable variation in general population sample selection methods and assessment of kidney function across studies. In addition, a clear description of the methods used was often lacking, and the reporting of CKD prevalence was heterogeneous. The approach of The European CKD Burden Consortium will not eliminate the differences in population selection methods and laboratory assessment of kidney function. However, the recommendations regarding the reporting of both methods and results of CKD prevalence studies may enhance comparability of CKD prevalence results across Europe and even worldwide \[[@GFV131C64]\]. Our recommendations may be used by investigators to optimize both the design and the reporting of future CKD prevalence studies.
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[Supplementary data are available online at http://ndt.oxfordjournals.org.](http://ndt.oxfordjournals.org/lookup/suppl/doi:10.1093/ndt/gfv131/-/DC1)
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###### Supplementary Data

[^1]: *N*, Number of subjects with creatinine measurement; n/a, not applicable.

[^2]: ^a^Authors refer to previous publication.

[^3]: Albuminuria = method of albuminuria measurement; CKD definition 1 = eGFR below 60 mL/min/1.73 m^2^ and or the presence of albuminuria \>30 mg/g (i.e. CKD Stages 1--5); 2 = eGFR below 60 mL/min/1.73 m^2^ (i.e. CKD Stages 3--5); 3 = albuminuria \>30 mg/g. Ethnicity = 'yes' if collection is reported; 'no' if not reported or not collected. CI, confidence interval given for prevalence estimate; CG, Cockcroft and Gault equation; n/a, not applicable.

[^4]: ^a^In order to standardize creatinine values, 1720 frozen serum samples were remeasured in a single laboratory with an IDMS-traceable enzymatic assay. Hereafter, equations relating the Jaffe and IDMS-traceable creatinine were developed to standardize all baseline values as follows: ScrIDMS = 0.86 × ScrJaffe + 4.40. \*Population corrected for sampling design (i.e. oversampling of albuminuria).
